Ts-Ting Lin
Overview
Explore the profile of Ts-Ting Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sung Y, Liu Y, Chao P, Chang C, Jin P, Lin T, et al.
Theranostics
. 2018 Feb;
8(4):894-905.
PMID: 29463989
Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib-a multikinase inhibitor drug-has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by...
2.
Chen Y, Liu Y, Sung Y, Ramjiawan R, Lin T, Chang C, et al.
Sci Rep
. 2017 Mar;
7:44123.
PMID: 28276530
Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). Inhibition of RAF kinases can induce a dose-dependent "paradoxical" upregulation of the downstream mitogen-activated protein kinase (MAPK)...
3.
Lin T, Gao D, Liu Y, Sung Y, Wan D, Liu J, et al.
J Control Release
. 2015 Nov;
221:62-70.
PMID: 26551344
Sorafenib is a tyrosine kinase inhibitor that has recently been shown to be a potential antifibrotic agent. However, a narrow therapeutic window limits the clinical use and therapeutic efficacy of...
4.
Liu J, Chiang T, Liu C, Chern G, Lin T, Gao D, et al.
Mol Ther
. 2015 Aug;
23(11):1772-1782.
PMID: 26278330
Antiangiogenic therapy has recently emerged as a highly promising therapeutic strategy for treating hepatocellular carcinoma (HCC). However, the only clinically approved systemic antiangiogenic agent for advanced HCC is sorafenib, which...
5.
Gao D, Lin T, Sung Y, Liu Y, Chiang W, Chang C, et al.
Biomaterials
. 2015 Jul;
67:194-203.
PMID: 26218745
Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) - yet associated with only moderate therapeutic effect and the high incidence of...